NCT02722148View on ClinicalTrials.gov

Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 21, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Eosinophilic Esophagitis
Interventions
DEVICE

Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy

A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).

Trial Locations (1)

27599

UNC Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02722148 - Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) | Biotech Hunter | Biotech Hunter